Kornimate/medical-research-clean huggingface dataset:
visceral adiposity index and overactive bladder

Conditions: Visceral Adiposity Index

Summary: in present study, we aimed to investigate the association between visceral adiposity index and overactive bladder symptoms in female patients aged over 18 years.between january-2015 and july-2017, 151 female patient with overactive bladder symptoms were evaluated in recep tayyip erdogan university training and research hospital urology department. antropometric and laboratory features including serum lipid levels, ast, alt, fasting glucose levels, and also urodynamic findings were recorded. visceral adiposity index was calculated according to gender-specific formula. participants were divided into two groups according to 7,55 cut-off level for visceral adiposity index levels. statistical significance were discussed between two groups.

antropometric and laboratory features including serum lipid levels, ast, alt, fasting glucose levels were recorded. urodynamic study was performed all of patients to evaluate bladder functions. over active bladder questionnaire-8 turkish validated short form was filled out and recorded for each patients. detailed medical histories of all patients were obtained before the study. height, weight, and waist circumference (wc) were measured with the subjects in their underwear. body mass ındex (bmi) was computed by the formula as the ratio of weight to the square of height (kg/m2). wc was measured on the line between the iliac crest and the lower costal margin parallel to the ground after subjects exhaled. inclusion criteria of study was female patients who have over active bladder symptomes with or without urinary incontinence. exclusion criterias of study were male gender, pregnancy, alcohol intake, bladder cancer history, previous incontinence surgery history, presence of neurological disease, urinary infection or bladder stone and pelvic radiotherapy history.

Eligibility criteria:
inclusion criteria: * female patients over 18 years aged with overactive bladder symptoms exclusion criteria: * male gender, pregnancy, alcohol intake, bladder cancer history, previous incontinence surgery history, presence of neurological disease, urinary infection or bladder stone and pelvic radiotherapy history

Keywords: obesity overactive bladder urinary incontinence visceral adiposity index waist circumference
clinical trial of efficacy and safety of the combination of reduced duration prophylaxis followed by immuno-guided prophylaxis in lung transplant recipients.

Conditions: Transplantation Infection; Cytomegalovirus Infections

Summary: to assess the efficacy of reduced duration prophylaxis followed by immuno-guided prophylaxis to prevent cytomegalovirus disease.

prolonged use of antivirals to prevent the development of cytomegalovirus (cmv) disease in lung transplant patients has been shown to have significant side effects, for which alternatives are being sought to reduce their use. the monitoring of cell immunity against cmv could be an alternative as it has shown to be useful in identifying transplant patients at low risk of infection, who could benefit from shorter prophylaxis. the aim of the cytocor study is to demonstrate that the combination of a reduced prophylaxis strategy with subsequent cmv-specific immunological monitoring would allow cmv infection to be controlled in lung transplant patients as effectively as the usual strategy (prophylaxis followed by pre-emptive therapy), while reducing the side effects of antivirals due to the shorter duration of prophylaxis.

Eligibility criteria:
inclusion criteria: * subjects with cytomegalovirus positive serology who underwent lung transplantation. * subjects of 18 years of age or older. * expected valgancilovir prophylactic treatment of 6 months after transplantation. * patients who have signed the informed consent form. exclusion criteria: * hiv infected subjects. * subjects unable to comply with the protocolo follow-up visits. * subjects who underwent multivisceral transplant. * pregnant and/or lactating women. * intolerance to valganciclovir/ganciclovir treatment.

Keywords: lung transplantation cytomegalovirus infection specific immunity
sunitinib malate related fatigue in patients with metastatic kidney cancer

Conditions: Fatigue; Recurrent Renal Cell Cancer; Stage IV Renal Cell Cancer

Summary: the purpose of this research study is to determine how sunitinib (sunitinib malate) causes fatigue. patients will be asked to complete a brief questionnaire (survey) to rate their levels of fatigue every two weeks while they are participating in this research study. the questionnaire takes approximately 10-15 minutes to complete and is 9 questions. a series of physical measurements for fatigue will be performed before the first dose of sunitinib and again (4) weeks later to see if there are any changes in physical level of fatigues

primary objectives: i. to determine the mechanisms associated with sunitinib related fatigue by recording emg signals during a submaximal elbow contraction, twitch force and tms prior to and at the end of 4 weeks of sunitinib in metastatic rcc patients. outline: patients receive sunitinib malate orally (po) daily for 4 weeks. patients undergo neuromuscular testing at baseline and on day 28 and complete fatigue assessment at baseline and on days 14 and 28. .

Eligibility criteria:
inclusion criteria: * histologically proven renal cell cancer with metastases; pathology from either primary or metastatic tumor; no histologic subtype restriction * evidence of measurable disease according to response evaluation criteria in solid tumors (recist) criteria version 1.1 or evaluable disease * eastern cooperative oncology group (ecog) performance score 0 to 1 * hemoglobin \>= 9 gram/dl * common terminology criteria for adverse events (ctcae) fatigue levels pre-treatment \< 2 * signed and dated informed consent exclusion criteria: * greater than 2 previous systemic treatments for rcc * heart failure, new york heart association (nyha) class 3 and 4 * unstable angina (defined as ongoing use of nitrates or cardiac ischemia in the prior 6 months) * arrhythmia uncontrolled by medication * hypertension (\> 160/90 mmhg) not controlled with medical management * brain metastases or previous cranial radiation, leptomeningeal cancer * surgery within 2 weeks of study entrance * history of stroke, myasthenia gravis, multiple sclerosis, polyneuropathy * pregnancy or breast feeding * central-nervous system active medications, intake or withdrawal of which lowers seizure threshold (determination made in consultation with study's responsible treating physician) * any history of epilepsy, convulsion or seizure * medication-resistant epilepsy in a first-degree relative * cochlear implants or internal pulse generators or cardiac pacemakers or intracardiac lines * metallic implants in the vicinity of discharging coil in the head or cervical spine * unexplained fainting spells/syncope or multiple concussions * history of severe head trauma (followed by loss of consciousness) * implanted brain or spinal cord electrodes/stimulation * medication infusion device * frequent/severe headaches or severe migraines * past or current medical history of diagnosed or undiagnosed tinnitus
comparison of analgesic methods, and their effects on patient recovery, following liver surgery

Conditions: Postoperative Pain

Summary: the provision of adequate pain relief following major liver surgery is essential, not only for patient comfort, but for the prevention of complications, such as chest infection. commonly, pain relief in the first few days after surgery is provided by epidural analgesia. drugs are delivered to the area around the spinal cord, through a fine plastic tube placed in the patients back, and this blocks sensation from the abdomen downwards, thereby providing effective pain relief without the need for opiate analgesia (e.g. morphine). opiate analgesia can cause nausea, drowsiness and constipation, and its use should be minimised. epidurals, however, can be associated with some problematic side effects. low blood pressure is commonly encountered, and not only can its treatment be associated with complications, but patients are often confined to bed. mobility can also be limited if muscle function in the legs, (in addition to sensation), is inadvertently affected by the epidural drugs. other problems associated with epidural use are the relatively common failure of the technique to provide adequate analgesia (20%), and some extremely rare but potentially disastrous complications of epidural insertion. an alternative technique, is the provision of pain relief directly into the wound, via one or more multi-holed tubes(catheters), placed either in or close to the wound. this technique alone does not provide as effective analgesia as a functioning epidural, but when combined with other intravenous or oral analgesia, has been shown to be effective following a variety of surgical procedures. it is hypothesised that, following major liver surgery, the use of this latter technique may result in superior outcome and faster recovery, when compared with epidural, by avoidance of the side effects and complications discussed above. in this study, patients scheduled to undergo major liver surgery at the royal infirmary of edinburgh with be randomly assigned to receive the first two days of pain relief either by epidural, or by wound catheter plus additional analgesia. both groups will then receive an identical oral analgesic regime for the remainder of the hospital stay. outcomes of interest will include the quality of pain relief attained, patient mobility, frequency of complications, and overall recovery time.


Eligibility criteria:
inclusion criteria: * patients undergoing open hepatic resection for benign or malignant conditions. * able to understand the nature of the study and what will be required of them. * men and non-pregnant, non-lactating women. * bmi 18-40. exclusion criteria: * patients with contraindication to either epidural or wound catheter techniques. * inability to give written, informed consent. * patients with dementia or neurological impairment. * patients with pre-existing condition limiting mobility. * underlying cirrhotic liver disease. * jaundice (bilirubin \> 50 μmol/l). * liver resection combined with secondary surgical procedure.

Keywords: postoperative care enhanced recovery hepatectomy analgesia
comparison of vigorous versus low intensity cool room treadmill training in people with multiple sclerosis

Conditions: Multiple Sclerosis; Neurological Rehabilitation; Exercise; Neuronal Plasticity; Cooling

Summary: new research in animal models of ms suggests that greater training intensity is required to restore lost functions. we have developed and tested vigorous intensity cool room treadmill training that people with ms who have fatigue and heat-sensitivity can tolerate. this study will focus on the appropriate dosage of training.

our previous research showed that vigorous aerobic training in a room cooled to 16°c can improve walking and measures of brain plasticity among people with ms related walking disability, especially in those who had fatigue and heat sensitivity. as a next step, we will compare our novel vigorous intensity cool room treadmill training to low intensity cool room treadmill walking and determine whether intensity is important in order to improve brain repair and restore walking among people with ms. our first objective is to compare the effects of 12 weeks of vigorous versus low intensity training on walking. our second objective is to determine whether treadmill training alters indicators of brain repair. we hypothesize that the cool room vigorous training will result in greater increases in walking and less fatigue, which will be sustained at follow-up. we also hypothesize that improvements will align with less brain inhibition (shortened csp measured using transcranial magnetic stimulation) and greater upregulation of the neurotrophin igf-1.

Eligibility criteria:
inclusion criteria: * people with a confirmed diagnosis of relapsing-remitting or progressive ms * older than 18 and less than 70 years of age * able to walk at least 10 meters with use of walking aids (expanded disability status scale (edss) \<7.0) * must be stable without relapse for at least 90 days exclusion criteria: * currently attending physical rehabilitation * functional community ambulators (gait speed\>120 cm/s) * a relapse of ms
facilitated telemedicine in the catholic health system

Conditions: HCV

Summary: hepatitis c virus is a leading cause of morbidity and mortality globally with the highest prevalence and incidence among people with opioid use disorder. we aim to establish facilitated telemedicine as a standard of care treatment approach at 3 opioid treatment programs operated by the catholic health system. this study is a chart review data analysis to evaluate outcomes of facilitated telemedicine integrated into opioid treatment programs and to evaluate the number of individuals who initiate and complete treatment for hepatitis c virus infection.

hepatitis c virus (hcv) is a leading cause of morbidity and mortality globally with the highest prevalence and incidence among people with opioid use disorder. in 2013, direct-acting antivirals were introduced for hcv treatment: all oral medications with minimal side effects and excellent efficacy when taken for 2-3 months. however, only 34% of eligible individuals received direct-acting antivirals between 2013 and 2022. moreover, hcv treatment with direct-acting antivirals was substantially lower among people with opioid use disorder. access to highly effective hcv treatment by the populations with the greatest need remains inadequate. to address this issue, we propose that facilitated telemedicine could be a bridge to integrate hcv treatment into opioid treatment programs. in our model, telemedicine encounters are facilitated by a case manager who is also a patient advocate and an educator. we recently completed a randomized clinical trial that compared facilitated telemedicine integrated into opioid treatment programs for hcv treatment compared to offsite referral. the hcv cure rate was 90.3% in facilitated telemedicine compared to 39.4% in offsite referral. in the proposed project, we seek to establish facilitated telemedicine as a standard of care treatment approach at 3 opioid treatment programs operated by the catholic health system.

Eligibility criteria:
inclusion criteria: * evidence of active hcv infection exclusion criteria: * no evidence of active hcv infection

Keywords: telemedicine
investigation of lung ventilation inhomogeneity in pediatric asthma

Conditions: Asthma

Summary: the primary objective of this study is to determine if well-controlled asthmatic patients followed in subspecialty asthma clinics between the ages of 3 - 18 years can be distinguished from healthy controls using lung clearance index, a parameter from the multiple breath washout test. also, to correlate lung clearance index with asthma sputum cell counts.

clinical studies are underway which are examining the utility of the lci in obstructive respiratory disease (cystic fibrosis and asthma). however, the majority of studies have examined asthmatics with ongoing evidence of reversible disease on spirometry. there is a very limited body of research comparing lci values in well-controlled asthmatics to healthy controls. furthermore, the type of inflammation occurring in asthma may have a different site of action, we will prospectively study whether there is a difference in lci between eosinophilic and neutrophilic inflammation to give us an indication of whether the site of non-eosinophilic inflammation is primarily in the small airways as well.

Eligibility criteria:
inclusion criteria: * asthma subjects: * 3 - 18 years of age at enrolment * clinically stable at enrolment * physician diagnosis of asthma and attending follow-up in the asthma clinic exclusion criteria: * asthma subjects: * born premature (before 37 weeks gestational age) * low birth weight (less than 2.5 kilograms) * history of congenital heart disease, neuromuscular disorder or bone disease * history of any chronic lung disease other than asthma * respiratory infection in last three weeks * change in medication in last three weeks (including oral steroids) * current or previous history of smoking

Keywords: pediatric lung ventilation inhomogeneity
effect of silkworms (bombyx mori l.) pupae extracts on musculoskeletal biomarkers in adults

Conditions: Sarcopenia

Summary: the investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of silkworms (bombyx mori l.) pupae extracts on muscle strength, muscle mass, and muscle function in adults with relative sarcopenia for 12 weeks.

a previous study has indicated that silkworms (bombyx mori l.) pupae extracts may increase muscle mass and strength. therefore, the investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of silkworms (bombyx mori l.) pupae extracts on muscle strength, muscle mass, and muscle function in adults with relative sarcopenia; the safety of the compound are also evaluated. the investigators examine the peak torque/body weight at 60°/s knee extension, handgrip strength, skeletal muscle mass, physical performance, and metabolic parameters at baseline, as well as after 12 weeks of intervention. fifty four adults were administered either 2,400 mg of silkworms (bombyx mori l.) pupae extracts or a placebo each day for 12 weeks.

Eligibility criteria:
inclusion criteria: * \<110% of the standard lean body mass as measured using the body composition analyzer * body mass index (bmi) ranging from 18.5 to 30.0 kg/m2 exclusion criteria: * vegetarian * history of any central bone fracture within 1 year * history of cancer or serious cerebro-cardiovascular diseases within 6 months * abnormal liver or renal function (more than twice the normal upper limit of the research institute) * uncontrolled diabetes mellitus (\>160 mg/dl of fasting blood sugar) * uncontrolled hypertension (\>160/100 mmhg) * uncontrolled thyroid diseases. * history of medication for psychiatric diseases such as severe affective disorder, schizophrenia, and substance use. * alcohol abuser * allergic reaction to constituent foods * severe gastrointestinal symptoms such as heartburn and indigestion * those who are pregnant, lactating, or planning to become pregnant during the clinical trial * those who have participated in other drug clinical trials within the last 3months
exercise and nutrition for head and neck cancer patients

Conditions: Cancer of Head and Neck

Summary: research on physical activity and nutrition interventions aimed at positively impacting symptom management, treatment-related recovery and quality of life has largely excluded head and neck cancer populations. this translates into a lack of clinical programming available for these patient populations. head and neck cancer patients deal with severe weight loss, with upwards of 70% attributed to lean muscle wasting, leading to extended recovery times, decreased quality of life (qol), and impaired physical functioning. to date, interventions to address body composition issues have focused solely on diet, despite findings that nutritional therapy alone is insufficient to mitigate changes. a combined physical activity and nutrition intervention, that also incorporates important educational components known to positively impact behaviour change, is warranted for this population. pilot work suggests that there is large patient demand and clinic support from the health care professionals for a comprehensive program. therefore, the purpose of the present study is to examine the impact of timing of a 12-week pa and nutrition intervention (either during or following treatment) for hn cancer patients on body composition, recovery, serum inflammatory markers and quality of life. in addition, the investigators will examine the impact of a 12-week maintenance program, delivered immediately following the intervention, on adherence, patient-reported outcomes (i.e., management of both physical and psychosocial treatment-related symptoms and side-effects), as well as return to work. the investigators hypothesize that (1) patients who are randomized to the intervention at treatment start will experience improved symptom management and decreased lean body composition changes, directly improving recovery and qol; (2) patients who receive a maintenance support program will have better long-term adherence and therefore superior treatment-related symptom management, physical and psychosocial functioning; and (3) return to work indices will improve and healthcare utilization costs will be lower in the participants who receive the immediate intervention (vs. delayed) as well as in those who receive the maintenance program (vs. no maintenance). this research will facilitate advancements in patient wellness, survivorship, and autonomy, and carve the path for a physical activity and wellness education model that can be implemented in other cancer centers.


Eligibility criteria:
inclusion criteria: * over 18 years of age * has received a diagnosis of nasopharyngeal, oropharyngeal or hypopharyngeal cancer * will receive radiation as part of treatment plan * able to walk without assistance * received clearance for exercise from treating oncologist * lives in calgary, alberta area * can speak and write english * is interested in participating in the study

Keywords: head/neck cancer exercise progressive strength training quality of life cancer randomized controlled trial nutrition lifestyle intervention